← Eichor
Condition: Small Lymphocytic Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Small Lymphocytic Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Phase 2 · 4 location(s) · Dana-Farber Cancer Institute · NCT05168930AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab a
Phase 1 · 31 location(s) · Hoffmann-La Roche · NCT05091424Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 · 50 location(s) · Eli Lilly and Company · NCT07218341Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Le
Phase 2 · 8 location(s) · National Cancer Institute (NCI) · NCT07061951Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Study on the Diagnosis and Management of CLL in Italy by GIMEMA
Phase N/A · 24 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04867915Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Phase 2 · 1 location(s) · Zulfa Omer · NCT07014917A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compar
Phase 3 · 187 location(s) · BeOne Medicines · NCT06943872A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
Phase 2 · 31 location(s) · AbbVie · NCT02966756The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocyti
Phase N/A · 6 location(s) · Canadian Cancer Trials Group · NCT05371808A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Phase 2 · 15 location(s) · Dizal Pharmaceuticals · NCT07154264A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04215809Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · 631 location(s) · National Cancer Institute (NCI) · NCT04269902Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Phase 2 · 1 location(s) · Zulfa Omer · NCT07108998DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Phase 2 · 17 location(s) · Dizal Pharmaceuticals · NCT06539182Mosunetuzumab for CLL MRD Clearance
Phase 1/Phase 2 · 2 location(s) · Inhye Ahn · NCT07052695Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Rec
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06967610A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Phase 1/Phase 2 · 127 location(s) · BeOne Medicines · NCT05006716A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymp
Phase 2 · 4 location(s) · VA Office of Research and Development · NCT06520098A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisoca
Phase N/A · 1 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06788639Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/Phase 2 · 1 location(s) · Medical University of South Carolina · NCT05702853
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.